Tolib B. Sanni

822 total citations
8 papers, 692 citations indexed

About

Tolib B. Sanni is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Tolib B. Sanni has authored 8 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Immunology. Recurrent topics in Tolib B. Sanni's work include Histone Deacetylase Inhibitors Research (4 papers), T-cell and B-cell Immunology (3 papers) and CAR-T cell therapy research (3 papers). Tolib B. Sanni is often cited by papers focused on Histone Deacetylase Inhibitors Research (4 papers), T-cell and B-cell Immunology (3 papers) and CAR-T cell therapy research (3 papers). Tolib B. Sanni collaborates with scholars based in United States and Netherlands. Tolib B. Sanni's co-authors include Роберто Пили, Brenda Salumbides, Henk M.W. Verheul, David Z. Qian, Peter Atadja, Yukihiko Kato, John E. Coligan, Hans J. Hammers, Juraj Kabát and Francisco Borrego and has published in prestigious journals such as The Journal of Immunology, Clinical Cancer Research and Molecular Biology of the Cell.

In The Last Decade

Tolib B. Sanni

8 papers receiving 680 citations

Peers

Countries citing papers authored by Tolib B. Sanni

Since Specialization

Citations

This map shows the geographic impact of Tolib B. Sanni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tolib B. Sanni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tolib B. Sanni more than expected).

Fields of papers citing papers by Tolib B. Sanni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tolib B. Sanni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tolib B. Sanni. The network helps show where Tolib B. Sanni may publish in the future.

Co-authorship network of co-authors of Tolib B. Sanni

This figure shows the co-authorship network connecting the top 25 collaborators of Tolib B. Sanni. A scholar is included among the top collaborators of Tolib B. Sanni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tolib B. Sanni. Tolib B. Sanni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors 2008 ·Clinical Cancer Research ·Henk M.W. Verheul, Brenda Salumbides, (unknown), Hans J. Hammers, David Z. Qian, Tolib B. Sanni, Peter Atadja, Роберто Пили	93
2	Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma 2007 ·Clinical Cancer Research ·Yukihiko Kato, Kiyoshi Yoshimura, Tahiro Shin, Henk M.W. Verheul, Hans J. Hammers, Tolib B. Sanni, Brenda Salumbides, (unknown), Richard D. Schulick, Роберто Пили	74
3	Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model 2007 ·Clinical Cancer Research ·Henk M.W. Verheul, Hans J. Hammers, (unknown), (unknown), Tolib B. Sanni, Brenda Salumbides, David Z. Qian, George D. Yancopoulos, Роберто Пили	92
4	Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma 2007 ·Molecular Cancer Therapeutics ·Yukihiko Kato, Brenda Salumbides, (unknown), David Z. Qian, Simon A. Williams, (unknown), Tolib B. Sanni, Peter Atadja, Роберто Пили	63
5	Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 2006 ·Clinical Cancer Research ·David Z. Qian, Yukihiko Kato, Shabana Shabbeer, (unknown), Henk M.W. Verheul, Brenda Salumbides, Tolib B. Sanni, Peter Atadja, Роберто Пили	233
6	The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor 2004 ·Molecular Immunology ·Francisco Borrego, Madhan Masilamani, Juraj Kabát, Tolib B. Sanni, John E. Coligan	70
7	Exclusion of Lipid Rafts and Decreased Mobility of CD94/NKG2A Receptors at the Inhibitory NK Cell Synapse 2004 ·Molecular Biology of the Cell ·Tolib B. Sanni, Madhan Masilamani, Juraj Kabát, John E. Coligan, Francisco Borrego	31
8	NK Cell CD94/NKG2A Inhibitory Receptors Are Internalized and Recycle Independently of Inhibitory Signaling Processes 2002 ·The Journal of Immunology ·Francisco Borrego, Juraj Kabát, Tolib B. Sanni, John E. Coligan	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact